FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

198 stories mentioning Eli Lilly and CompanyUpdated 2d ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

What are analysts saying about Eli Lilly and Company?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on Eli Lilly and Company?

Wire

Eli Lilly Reportedly Launches Foundayo Weight-Loss Pill in UK

Eli Lilly (LLY) has launched its Foundayo weight-loss pill in the UK, making Britain the first European country where the oral treatment is available, multiple news outlets reported Monday, citing a company statement.The once-daily medication is initially available through private prescription for weight management and type 2 diabetes while undergoing review for state health coverage, the reports said.The treatment is expected to cost between 100 British pounds ($136.4) and 120 pounds monthly, according to the reports. Foundayo, or orforglipron, was authorized by the UK's Medicines and Healthcare products Regulatory Agency about two weeks ago.Eli Lilly did not immediately respond to' request for comment.Shares of the company were down 1.2% in Monday trading.Price: $1240.13, Change: $-15.27, Percent Change: -1.22%

$LLY
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.2%.The iShares Biotechnology ETF (IBB) added 1.8%.In corporate news, OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery program, while raising its fiscal 2026 cash and cash equivalents guidance. OmniAb shares jumped nearly 13%, and Lilly was up 0.4%.Freenome (FRNM) shares surged past 12% after Jefferies initiated coverage of the stock with a buy rating and a price target of $17.Argenx (ARGX) shares climbed 16% after the company said a phase 3 study evaluating its experimental drug Vyvgart Hytrulo in adults with autoimmune myositis met its main goal.EyePoint (EYPT) shares tumbled 67% after it said its phase 3 Lugano trial testing Duravyu in people with wet age-related macular degeneration failed to achieve its primary endpoint.

$ARGX$EYPT$FRNM$LLY$OABI
Sectors

Sector Update: Healthcare

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.3%.The iShares Biotechnology ETF (IBB) added 1.7%.In corporate news, OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery program, while raising its fiscal 2026 cash and cash equivalents guidance. OmniAb shares jumped 12%, and Lilly was up 0.4%.

$LLY$OABI
Wire

Top Midday Gainers

OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery program, while raising its fiscal 2026 cash and cash equivalents guidance.Shares of OmniAb jumped over 11%, with intraday trading volume rising to more than 16.4 million from the stock's daily average of about 647,000.Meanwhile, B. Riley raised its price target for RCM Technologies' (RCMT) shares to $45 from $40 while keeping its buy rating.Shares climbed 13% amid an increase in intraday trading volume to over 320,000 from a daily average of about 63,000.Nvidia (NVDA) has reported a $29.99 billion stake in Intel (INTC) and a $20.98 billion stake in Space Exploration Technologies (SPCX) as of June 30, according to a Form 13F filed Friday with the US Securities and Exchange Commission.Shares of SpaceX rose 6%, with intraday trading volume at over 84.5 million, versus the stock's daily average of about 122.1 million.Price: $3.78, Change: $+0.40, Percent Change: +11.83%

$INTC$LLY$NVDA$OABI$RCMT$SPCX
Wire

OPKO Health Issues Additional $125 Million in Senior Notes Secured by Mazdutide Royalties

OPKO Health (OPK) said Thursday it issued $125 million of additional senior secured notes to HealthCare Royalty, a business of KKR (KKR).The notes, secured by OPKO's royalty interests arising from its mazdutide agreement with Eli Lilly (LLY), will mature in 2044, matching the maturity of OPKO's existing notes with HealthCare Royalty, the company said.The financing gives OPKO additional non-dilutive capital without issuing equity, while allowing it to retain future royalty income after total payments under the financing reach a cap of 1.5 times the amount funded, according to OPKO.The company said Innovent Biologics is commercializing mazdutide in China, while OPKO receives royalties from commercial sales under its licensing agreement with Lilly.OPKO said it began recognizing mazdutide royalty revenue in 2025.Shares of OPKO were up 1.4% in Thursday trading, while KKR and Eli Lilly were less than 1% higher.Price: $1.42, Change: $+0.03, Percent Change: +1.80%

$KKR$LLY$OPK
Insider Trading

Eli Lilly Insider Sold Shares Worth $2,370,020, According to a Recent SEC Filing

Donald A Zakrowski, Senior Vice President, Finance, & Chief Accounting Officer, on August 10, 2026, sold 2,000 shares in Eli Lilly (LLY) for $2,370,020. Following the Form 4 filing with the SEC, Zakrowski has control over a total of 3,261 common shares of the company, with 1,526 shares held directly and 1,735 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/59478/000005947826000083/xslF345X05/wk-form4_1786480313.xml

$LLY
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) decreased less than 0.1%.In corporate news, Tactile Systems Technology (TCMD) shares fell past 17% after it reported late Monday its Q2 results and lowered its revenue guidance for the full year.Alamar Biosciences (ALMR) reported a narrower Q2 net loss and sales above consensus late Monday. Its shares surged past 32%.Hims & Hers Health (HIMS) shares fell 2.5%. Q2 results were mixed, with upside in its US business from branded GLP-1 strength and a ramp in testosterone offset by disappointing gross margin and weak free cash flow, Morgan Stanley said.Eli Lilly (LLY) committed to use Veeva Systems' (VEEV) Veeva Vault CRM globally. Lilly shares were down 1.3%, and Veeva added 1%.

$ALMR$HIMS$LLY$TCMD$VEEV
Sectors

Sector Update: Healthcare Stocks Softer Tuesday Afternoon

Healthcare stocks declined Tuesday afternoon with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.3%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, Hims & Hers Health (HIMS) shares fell 1.9%. Q2 results were mixed, with upside in its US business from branded GLP-1 strength and a ramp in testosterone offset by disappointing gross margin and weak free cash flow, Morgan Stanley said.Eli Lilly (LLY) committed to use Veeva Systems' (VEEV) Veeva Vault CRM globally. Lilly shares fell 0.9%, and Veeva added 1%.AC Immune's (ACIU) ACI-7104, for the potential treatment of early-stage Parkinson's disease, received US Food and Drug Administration fast-track designation and investigational new drug clearance. The shares jumped 14%.

$ACIU$HIMS$LLY$VEEV
Wire

Rothschild & Co Redburn Adjusts Eli Lilly and Co. PT to $915 From $900, Keeps Neutral Rating

Eli Lilly and Co. (LLY) has an average rating of overweight and mean price target of $1,328.08, according to analysts polled by FactSet.Price: $1222.27, Change: $-9.67, Percent Change: -0.78%

$LLY
Insider Trading

Eli Lilly Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing

Anat Hakim, Executive Vice President, General Counsel & Secretary, on August 07, 2026, sold 5,000 shares in Eli Lilly (LLY) for $5,950,000. Following the Form 4 filing with the SEC, Hakim has control over a total of 50,562 common shares of the company, with 22,987 shares held directly and 27,575 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/59478/000168555626000006/xslF345X05/wk-form4_1786393159.xml

$LLY
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for orforglipron, marketed as Foundayo, a once-daily tablet for weight management and type 2 diabetes, the Medicines and Healthcare products Regulatory Agency said Monday. Lilly shares gained 3.7%.Teledyne Technologies (TDY) has agreed to acquire X-ray imaging components manufacturer Varex Imaging (VREX) in a $1.1 billion deal that will expand its X-ray device portfolio to include oncology detectors. Teledyne shares were up 0.3%, and Varex surged 48%.Thermo Fisher Scientific (TMO) expects to increase its customer base in India by 15% to 20% over the next five years, driven by growth in biopharma research and manufacturing, Reuters reported, citing Srinath Venkatesh, the company's managing director for India and South Asia. Thermo Fisher shares were up 0.7%.Silence Therapeutics (SLN) shares jumped 27% after it said Monday its phase 2 trial of divesiran to treat Polychthemia Vera, a form of blood cancer, met its primary endpoint.

$LLY$SLN$TDY$TMO$VREX
Sectors

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for orforglipron, marketed as Foundayo, a once-daily tablet for weight management and type 2 diabetes, the Medicines and Healthcare products Regulatory Agency said Monday. Lilly shares gained 2.6%.Teledyne Technologies (TDY) has agreed to acquire X-ray imaging components manufacturer Varex Imaging (VREX) in a $1.1 billion deal that will expand its X-ray device portfolio to include oncology detectors. Teledyne shares were up 0.6%, and Varex surged 48%.Thermo Fisher Scientific (TMO) expects to increase its customer base in India by 15% to 20% over the next five years, driven by growth in biopharma research and manufacturing, Reuters reported, citing Srinath Venkatesh, the company's managing director for India and South Asia. Thermo Fisher shares were up 0.2%.Sionna Therapeutics (SION) shares fell nearly 92% after it said Monday it won't advance SION-719 as an add-on therapy to standard of care Trikafta in cystic fibrosis patients after a phase 2a proof-of-concept failed to meet its key activity endpoint of sweat chloride reduction.

$LLY$SION$TDY$TMO$VREX
Wire

Eli Lilly's Orforglipron Gains First European Approval in UK

Eli Lilly and Co. (LLY) received UK authorization for orforglipron, marketed as Foundayo, a once-daily tablet for weight management and type 2 diabetes, the Medicines and Healthcare products Regulatory Agency said Monday.The UK is the first country in Europe to authorize the GLP-1 tablet for weight management and type 2 diabetes.The oral treatment is cleared for weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity, in adults with a BMI of 30 or higher, or a BMI from 27 to 30 with at least one weight-related condition, MHRA said.Patients take the pill daily without food or water restrictions, starting at 0.8 mg before escalating through several dose levels to 17.2 mg, with a minimum of one month at each dose level, the agency said.The therapy also is authorized to improve glycemic control in patients with insufficiently controlled type 2 diabetes, it said.Price: $1200.01, Change: $+14.68, Percent Change: +1.24%

$LLY
Wire

Eli Lilly's Incretin Performance Supports Long-Term Growth, Truist Says

Eli Lilly and Company's (LLY) strong incretin performance supports its long-term growth outlook, though pricing dynamics and one-off events could temper revenue growth in the second half of 2026, Truist said in a Thursday note.The brokerage said Lilly's commercial contracting strategy should continue allowing pricing concessions that are more than offset by volume gains.It also said the US incretin portfolio still has room to grow, supported by the Medicare Bridge program, expanded formulary access through CVS Caremark and increased direct-to-consumer marketing.Truist expects Lilly's 2026 revenue to reach $87.3 billion, above the company's $85 billion to $87 billion guidance range.The investment firm said Lilly's full-year guidance appears conservative given strong second-quarter incretin volume growth and initiatives including broader commercial coverage, Medicare expansion and international market penetration.Truist reiterated its buy rating on the stock and raised its price target to $1,376 from $1,370.Price: $1187.15, Change: $+17.29, Percent Change: +1.48%

$LLY
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.5%.In corporate news, Eli Lilly (LLY) shares rose 4.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 3.8%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares added 0.6%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose 3.5%, and Bristol Myers Squibb fell 3.2%.Charles River Laboratories (CRL) on Wednesday reported fiscal Q2 non-GAAP earnings and sales above market expectations and raised its 2026 non-GAAP EPS guidance. Its shares jumped 11%.

$AZN$BMY$CRL$CVS$LLY$NVO
CVS, Eli Lilly Forge Partnership on Improved GLP-1 Access; Companies Top Second-Quarter Views
US Markets

CVS, Eli Lilly Forge Partnership on Improved GLP-1 Access; Companies Top Second-Quarter Views

CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-consumer weight-management offerings, while both companies reported higher-than-expected second-quarter results Wednesday.The collaboration with drugmaker Lilly will provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy via the CVS Health app, the retail pharmacy chain said. The tie-up promises to offer transparent pricing, including reimbursed and self-pay options, for the drugs by early in the fourth quarter.Lilly didn't immediately respond to' request for comment on the collaboration.The collaboration is part of a broader effort by CVS to enhance its DTC weight-management program, with MinuteClinic digital weight-loss visits lowered to $29, among other things. CVS Pharmacy offers all Food and Drug Administration-approved Glucagon-like peptide-1s, whether through insurance or cash-pay options.Separately, CVS reported that its second-quarter adjusted earnings rose to $2.58 a share from $1.81 a year earlier, exceeding the FactSet-polled consensus of $1.85. Revenue grew 7.3% to $106.1 billion, topping Wall Street's $100.03 billion views.The company now expects 2026 adjusted EPS between $7.90 and $8.10, compared with its prior outlook range of $7.30 to $7.50 and above the Street's $7.45 forecast. The updated guidance accounts for gains in the healthcare benefits and pharmacy and consumer wellness segments "while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds" CVS said in an earnings release.Separately, Lilly reported non-GAAP EPS of $8.38 for the June quarter, up from $6.31 a year earlier, surpassing the FactSet-polled consensus of $6.17. Revenue surged 48% to $22.97 billion, while analysts projected $20.69 billion.The drugmaker raised its 2026 revenue outlook to a range of $85 billion to $87 billion from the previous guidance of $82 billion to $85 billion. The company narrowed its full-year non-GAAP EPS forecast to between $35.50 and $36.50 from its previous range of $35.50 to $37. Analysts are looking for full-year non-GAAP EPS of $35.16 on revenue of $85.39 billion."(The second quarter) continued Lilly's strong momentum," Chief Executive David Ricks said on an earnings call, according to a FactSet transcript. "We delivered robust revenue across all key products and major geographies."Lilly shares were up 4.1% in Wednesday afternoon trade, while CVS fell 5.1%.Price: $99.45, Change: $-4.98, Percent Change: -4.76%

$CVS$LLY
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1%.The iShares Biotechnology ETF (IBB) increased 0.9%.In corporate news, Eli Lilly (LLY) shares rose 3.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 4.9%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares rose 1.3%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose nearly 4%, and Bristol Myers Squibb fell 3.5%.

$AZN$BMY$CVS$LLY$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks advanced Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1%.The iShares Biotechnology ETF (IBB) increased 0.9%.In corporate news, Eli Lilly (LLY) shares rose 3.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 4.9%.

$CVS$LLY
Wire

Top Midday Stories: SpaceX Shares Fall After Inaugural Results; AMD Drops Despite Strong Q2 EPS, Revenue

US equities were mixed and crude oil eased in late-morning trading Wednesday as investors remained hopeful that a deal to reopen the Strait of Hormuz may be reached soon by the US and Iran.In company news, Space Exploration Technologies (SPCX) reported a Q2 loss late Tuesday of $0.09 per diluted share, narrowing from the loss of $0.34 a year earlier. Analysts surveyed by FactSet expected a loss of $0.23. Revenue rose to $7.81 billion from $4.07 billion, topping the $6.83 billion consensus. CEO Elon Musk said SpaceX will build its AI services exclusively on Nvidia's (NVDA) systems. SpaceX shares fell 8.6% around midday, and Nvidia rose 3.4%.Advanced Micro Devices (AMD) reported fiscal Q2 adjusted diluted EPS late Tuesday of $1.66, up from $0.48 a year earlier, above the $1.62 consensus. Revenue rose to $11.64 billion from $7.69 billion, exceeding the $11.31 billion market estimate. The company expects Q3 revenue of $13 billion, plus or minus $300 million, compared with the $12.54 billion consensus. AMD shares fell 6.8%.Shopify (SHOP) reported Q2 EPS of $1.16, up from $0.69 a year earlier and above the $0.30 consensus. Revenue rose to $3.58 billion from $2.68 billion, exceeding the $3.43 billion estimate. The company expects Q3 revenue to gain more than 30%. Shopify shares jumped 17%.Walt Disney (DIS) reported fiscal Q3 adjusted diluted EPS of $2.06, up from $1.61 a year earlier and above the $1.86 consensus. Revenue rose to $25.25 billion from $23.65 billion, trailing the $25.39 billion estimate. Disney shares rose 1.9%.Eli Lilly (LLY) reported Q2 non-GAAP EPS of $8.38, up from $6.31 a year earlier and above the $6.01 consensus. Revenue rose to $22.97 billion from $15.56 billion, topping the $20.69 billion consensus. The company expects full-year non-GAAP EPS of $35.50 to $36.50, compared to previous guidance of $35.50 to $37. Revenue is expected to be $85 billion to $87 billion, up from the prior forecast of $82 billion to $85 billion. Analysts expect EPS of $35.04 on revenue of $85.28 billion. Separately, CVS Health (CVS) is revamping its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. Shares of Lilly rose 2.8%, and CVS dropped 5.8%.Uber Technologies (UBER) reported Q2 non-GAAP EPS of $0.81, up from $0.60 a year earlier and matching the consensus. Revenue rose to $14.19 billion from $12.65 billion, trailing the $14.24 billion consensus. The company expects Q3 non-GAAP EPS of $0.84 to $0.88, compared with the $0.87 market estimate. Uber shares fell 6.6%.Price: $114.57, Change: $-10.77, Percent Change: -8.59%

$AMD$CVS$DIS$LLY$NVDA$SHOP$SPCX$UBER
Sectors

Sector Update: Healthcare Stocks Rise Premarket Wednesday

Healthcare stocks were rising premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.9% and the iShares Biotechnology ETF (IBB) up 0.4%.Eli Lilly (LLY) shares were up more than 4% after the company posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance.CVS Health (CVS) reported higher Q2 adjusted earnings and revenue, and lifted its 2026 non-GAAP EPS outlook. Shares of CVS Health were down more than 7% pre-bell.Cencora (COR) stock was up more than 2% after the company posted higher fiscal Q3 adjusted earnings and revenue in addition to lifting its fiscal 2026 non-GAAP EPS outlook.

$COR$CVS$IBB$LLY$XLV

Showing 21-40 of 198

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company